The FDA granted approval to Insmed's Brinsupri, a first-of-its-kind therapy targeting neutrophilic inflammation in non-cystic fibrosis bronchiectasis (NCFB), impacting approximately 500,000 patients in the US, with millions affected globally. The approval follows positive data from phase III ASPEN and other clinical trials demonstrating reduction in exacerbations by addressing a root disease mechanism. The announcement generated significant investor optimism, with Insmed shares surging 17% post-approval and analysts projecting blockbuster sales potential. Experts herald the drug as a new standard of care in NCFB management.